Serous retinal detachment associated with diabetic macular edema over the course of Ranibizumab treatment

Abstract

AbstractPurpose Diabetic macular edema (DME) is frequently associated with subretinal detachment (SRD). SRD does not seem associated with a change of spontaneous evolution of DME. But we do not know wether SRD has an impact on DME resolution under intravitreal injections (IVT) of Ranibizumab. The purpose of our study was to describe the course of DME treated by Ranibizumab with or without SRD over 6 months.Methods We retrospectively enrolled patients treated by ranibizumab for DME with central foveal thickness (CFT) > 300 µm between November 2012 and November 2013. Group 1 was DME with SRD and group 2 was DME without SRD. We measured manually SRD on a SD‐OCT (OPKO). We studied best corrected visual acuity (BCVA), BCVA variation from baseline, CFT with or without SRD on OCT and the total number of IVT over 6 months.Results 48 eyes with DME of 40 patients were included. 23 eyes (47,9 %) had SRD at baseline (group 1) and 25 eyes (41 %) did not (group 2). At baseline, BCVA in decimal was 0,19 (40,3 letters in ETDRS) in group 1 and 0,25 (51,3 letters ETDRS) in group 2 (p<0,05). CFT was 666µm and SRD was 215µm in group 1 and 528µm in group 2. After 6 months, mean change of BCVA was + 0,21 in decimal (+ 20,9 letters in ETDRS) in group 1, and + 0,17 in decimal (+ 7,8 letters ETDRS) in group 2 (p < 0,05). The final CFT was 327µm in group 1 (‐ 339 µm) and 379 µm (‐ 147µm) in group 2. Group 1 received 4,3 IVT over 6 months against 4,2 IVT in group 2.Conclusion DME with SRD had a thicker CFT and a lower BCVA at baseline than DME without SRD in our case series. DME with SRD seemed to have the best results under ranibizumab regarding BCVA, and CFT after treatment.SRD associated with DME seems to be a good functiona